Short-course of oral miltefosine for treatment of visceral leishmaniasis.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 11049800.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.
Medical subject headings
- Antiprotozoal Agents
- Leishmaniasis, Visceral
- Phosphorylcholine